<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="163165">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01958996</url>
  </required_header>
  <id_info>
    <org_study_id>OROCIEP</org_study_id>
    <nct_id>NCT01958996</nct_id>
  </id_info>
  <brief_title>Phase I/II Study of Escalating Doses of Idarubicin Orally Given With Oral Cyclophosphamide, Etoposide, Prednisolone and Intravenous Rituximab in Elderly Patient With Disseminated High Grade Non Hodgkin Lymphoma</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      R-CHOP with doxorubicin is the standard first line treatment of high grade non-Hodgkin's
      lymphoma. In order to avoid central venous system insertion and reduce hospitalization time
      in elderly patients, we developed an oral chemotherapy treatment:  &quot; OROCIEP&quot;trial.

      Nineteen patients were enrolled and 127 chemotherapy cycles were available for toxicities.
      The estimated two-years overall survival was 74%. The main haematological toxicity was
      neutropenia.

      This study is still ongoing to confirm recommended dose of oral anthracycline.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2009</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Maximum tolerated dose of idarubicin</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Remission rate after 4 cycles and 8 cycles</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <condition>High Grade Lymphomas CD20 +</condition>
  <arm_group>
    <arm_group_label>idarubicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>idarubicin</intervention_name>
    <arm_group_label>idarubicin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CD20-positive diffuse large B-cell lymphoma.WHO classification (55)

          -  Written informed consent

          -  Age &gt; 65 and &lt; 80 years

          -  Performance status (ECOG) &lt;3

          -  measurable disease

          -  Serology  HIV negative, Hepatites B, Hepatites C negative

        Exclusion Criteria:

          -  Serology HIV positive, Hepatite B positive, Hepatite C positive

          -  Cardiac failure.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Vincent DELWAIL, MD</last_name>
    <phone>0033 5 49 44 45 41</phone>
    <email>vincent.delwail@chu-poitiers.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent DELWAIL, MD</last_name>
      <phone>0033 5 49 44 45 41</phone>
      <email>vicent.delwail@chu-poitiers.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 8, 2013</lastchanged_date>
  <firstreceived_date>October 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Idarubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
